3-36993599-C-T
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 4P and 1B. PP3_StrongBP6
The NM_001167617.3(MLH1):c.-465C>T variant causes a 5 prime UTR premature start codon gain change. The variant allele was found at a frequency of 0.0000688 in 1,614,086 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.000033 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000073 ( 0 hom. )
Consequence
MLH1
NM_001167617.3 5_prime_UTR_premature_start_codon_gain
NM_001167617.3 5_prime_UTR_premature_start_codon_gain
Scores
18
1
Clinical Significance
Conservation
PhyloP100: 5.72
Genes affected
MLH1 (HGNC:7127): (mutL homolog 1) The protein encoded by this gene can heterodimerize with mismatch repair endonuclease PMS2 to form MutL alpha, part of the DNA mismatch repair system. When MutL alpha is bound by MutS beta and some accessory proteins, the PMS2 subunit of MutL alpha introduces a single-strand break near DNA mismatches, providing an entry point for exonuclease degradation. The encoded protein is also involved in DNA damage signaling and can heterodimerize with DNA mismatch repair protein MLH3 to form MutL gamma, which is involved in meiosis. This gene was identified as a locus frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.949
BP6
Variant 3-36993599-C-T is Benign according to our data. Variant chr3-36993599-C-T is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 134656.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=12, not_provided=1}.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.52C>T | p.Arg18Cys | missense_variant | 1/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.52C>T | p.Arg18Cys | missense_variant | 1/19 | 1 | NM_000249.4 | ENSP00000231790.3 |
Frequencies
GnomAD3 genomes AF: 0.0000329 AC: 5AN: 152204Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
5
AN:
152204
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251420Hom.: 0 AF XY: 0.0000294 AC XY: 4AN XY: 135916
GnomAD3 exomes
AF:
AC:
8
AN:
251420
Hom.:
AF XY:
AC XY:
4
AN XY:
135916
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000725 AC: 106AN: 1461882Hom.: 0 Cov.: 31 AF XY: 0.0000688 AC XY: 50AN XY: 727244
GnomAD4 exome
AF:
AC:
106
AN:
1461882
Hom.:
Cov.:
31
AF XY:
AC XY:
50
AN XY:
727244
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000329 AC: 5AN: 152204Hom.: 0 Cov.: 33 AF XY: 0.0000403 AC XY: 3AN XY: 74350
GnomAD4 genome
AF:
AC:
5
AN:
152204
Hom.:
Cov.:
33
AF XY:
AC XY:
3
AN XY:
74350
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
1
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:15Benign:2Other:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:5
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Nov 11, 2022 | The frequency of this variant in the general population, 0.00007 (8/113708 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with colorectal cancer (PMID: 14635101 (2003), 25559809 (2015)), a Lynch syndrome associated cancer and/or polyps (PMID: 25980754 (2015), 21404117 (2011)), pediatric cancer (PMID: 26580448 (2015)), uveal melanoma (PMID: 29625052 (2018)), and breast cancer (PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/MLH1)). It has also been reported in unaffected individuals (PMID: 24728327 (2014), PMID: 33471991 (2021), see also LOVD (http://databases.lovd.nl/shared/genes/MLH1)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. - |
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 05, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in individuals suspected of having Lynch syndrome, including at least one individual whose tumor showed microsatellite instability (PMID: 21404117, 14635101, 25559809, 25980754); This variant is associated with the following publications: (PMID: 24728327, 14635101, 22949387, 21404117, 25980754, 25559809, 26296696, 32008151, 29625052, 26580448, 36451132, 32601921, 33471991, 35980532, 22753075) - |
Uncertain significance, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | MLH1: PP3 - |
not specified Uncertain:3Other:1
not provided, no classification provided | reference population | ITMI | Sep 19, 2013 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Oct 21, 2024 | Variant summary: MLH1 c.52C>T (p.Arg18Cys) results in a non-conservative amino acid change located in the N-terminal domain (IPR002099) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251420 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.52C>T has been reported in the literature in individuals affected with features of Hereditary Nonpolyposis Colorectal Cancer without strong evidence of causality (e.g. Taylor_2003, Hardt_2011, Yurgelun_2015, Chubb_2015). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 22949387, 21404117, 14635101, 24728327, 25980754, 25559809, 26580448). ClinVar contains an entry for this variant (Variation ID: 134656). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Oct 14, 2020 | DNA sequence analysis of the MLH1 gene demonstrated a sequence change, c.52C>T, in exon 1 that results in an amino acid change, p.Arg18Cys. This sequence change has been reported in a patient with early onset proximal colorectal cancer with microsatellite instability and a family history of CRC in a sibling (PMID: 25559809). It has also been reported in few other patients with colorectal cancer but no additional patient specific clinical information was provided (PMIDs: 25980754, 21404117, and 14635101). This sequence change has been described in the gnomAD database with a low population frequency of 0.0032% (dbSNP rs367654552). The p.Arg18Cys change affects a highly conserved amino acid residue located in a domain of the MLH1 protein that is known to be functional. The p.Arg18Cys substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Due to these contrasting evidences and the lack of functional studies, the clinical significance of the p.Arg18Cys change remains unknown at this time. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | Feb 10, 2016 | - - |
Colorectal cancer, hereditary nonpolyposis, type 2 Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 06, 2024 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Sep 09, 2016 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Mar 14, 2023 | This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. - |
Hereditary cancer-predisposing syndrome Uncertain:2Benign:1
Uncertain significance, criteria provided, single submitter | curation | Sema4, Sema4 | Nov 16, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 04, 2019 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jan 09, 2023 | This missense variant replaces arginine with cysteine at codon 18 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with Lynch syndrome-associated cancer and/or colorectal polyps (PMID: 14635101, 21404117, 25559809, 25980754) or breast cancer (PMID: 32601921), and has also been in a healthy control (PMID: 24728327). This variant has been identified in 8/251420 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
Lynch syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jul 29, 2024 | This missense variant replaces arginine with cysteine at codon 18 of the MLH1 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in individuals affected with Lynch syndrome-associated cancer and/or colorectal polyps (PMID: 14635101, 21404117, 25559809, 25980754) or breast cancer (PMID: 32601921, 33471991), and has also been in healthy controls (PMID: 24728327, 33471991). This variant has been identified in 8/251420 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. - |
MLH1-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Dec 15, 2023 | The MLH1 c.52C>T variant is predicted to result in the amino acid substitution p.Arg18Cys. This variant has been reported in at least five individuals with either suspected Lynch syndrome or a personal and family history of colorectal cancer (Taylor et al. 2003. PubMed ID: 14635101; Hardt et al. 2011. PubMed ID: 21404117; Chubb et al. 2015. PubMed ID: 25559809; Yurgelun et al. 2015. PubMed ID: 25980754). It has also been reported in two individuals with acute lymphoblastic leukemia (Zhang et al. 2015. PubMed ID: 26580448) and one individual with uveal melanoma (Huang et al. 2018. PubMed ID: 29625052). This variant is reported in 0.0070% of alleles in individuals of European (Non-Finnish) descent in gnomAD and is classified as a variant of uncertain significance by the vast majority of sources in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/134656/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 18, 2023 | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 18 of the MLH1 protein (p.Arg18Cys). This variant is present in population databases (rs367654552, gnomAD 0.006%). This missense change has been observed in individual(s) with melanoma, acute lymphocytic leukemia and/or clinical features of Lynch syndrome (PMID: 14635101, 21404117, 22144684, 25980754, 26580448, 29625052). ClinVar contains an entry for this variant (Variation ID: 134656). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MLH1 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H
PrimateAI
Pathogenic
D
PROVEAN
Pathogenic
D
REVEL
Pathogenic
Sift
Pathogenic
D
Sift4G
Pathogenic
D
Polyphen
D
Vest4
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at